Codex Genetics utilizes next-generation sequencing and AI-powered analytics to provide clinically actionable genetic tests for cancer and pharmacogenomics, enabling personalized treatment plans based on individual genetic profiles. Their CoGenesis® platform accelerates diagnosis and management of genetic disorders, helping clinicians optimize drug response and improve patient outcomes.
Funding
$41.3K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for diagnosing and managing genetic disorders, cancer, and determining drug response often lack the precision needed for personalized treatment plans. Traditional genetic testing methods can be slow and may not provide comprehensive insights into individual genetic variations impacting health outcomes.
Solution
Codex Genetics offers clinically actionable genetic tests utilizing next-generation sequencing (NGS) and AI-powered analytics to enable precision medicine. The CoGenesis® platform accelerates the diagnosis and management of various conditions, including neurodegenerative diseases, cancer, and cardiovascular disorders, by identifying the root cause of diseases and providing targeted treatment plans based on individual genetic variances. The platform translates genetic, clinical, and radiological data into actionable insights, helping clinicians optimize drug response, understand cancer susceptibility, and improve overall patient outcomes. Codex Genetics' services facilitate early detection, personalized treatment strategies, and informed medical decision-making.
Target Audience
Codex Genetics serves patients experiencing symptoms or with a family history of genetic diseases, as well as universities, clinical trial centers, pharmaceutical companies, and hospitals seeking precision medicine solutions.
Features
- CoGenesis® platform leverages machine learning and big data analytics for variant discovery and clinical reporting.
- Next-Generation Sequencing (NGS) enables rapid analysis of DNA and RNA samples, delivering results faster than traditional methods.
- Comprehensive genetic testing services for hereditary cancer, neurodegenerative diseases, drug response, congenital cardiovascular diseases, and metagenomics.
- Professional solutions including the CoGenesis® Bioinformatics platform for accurate and efficient data interpretation.
- Tests to understand cancer susceptibility, facilitate early detection, and inform family planning.
- Drug response tests to optimize chronic disease management through personalized drug options and dosage adjustments.
- Pan-cancer treatment selection tests to prioritize targeted therapies and immunotherapies.
- Option to explore features of neurodegenerative diseases and cancers through a professional dashboard.